Full Name
Thuan Heng, Charles Chuah
Variants
Chuah, C.
Chuah, Charles T.H.
 
 
 
Email
gmscthc@nus.edu.sg
 

Publications

Results 1-13 of 13 (Search time: 0.009 seconds).

Issue DateTitleAuthor(s)
12013A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasCortes, J.E.; Kim, D.-W.; Pinilla-Ibarz, J.; Le Coutre, P.; Paquette, R.; Chuah, C. ; Nicolini, F.E.; Apperley, J.F.; Khoury, H.J.; Talpaz, M.; DiPersio, J.; DeAngelo, D.J.; Abruzzese, E.; Rea, D.; Baccarani, M.; Müller, M.C.; Gambacorti-Passerini, C.; Wong, S.; Lustgarten, S.; Rivera, V.M.; Clackson, T.; Turner, C.D.; Haluska, F.G.; Guilhot, F.; Deininger, M.W.; Hochhaus, A.; Hughes, T.; Goldman, J.M.; Shah, N.P.; Kantarjian, H.
217-Nov-2011Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasNicolini, F.E.; Basak, G.W.; Soverini, S.; Martinelli, G.; Mauro, M.J.; Müller, M.C.; Hochhaus, A.; Chuah, C. ; Dufva, I.H.; Rege-Cambrin, G.; Saglio, G.; Michallet, M.; Labussière, H.; Morisset, S.; Hayette, S.; Etienne, G.; Olavarria, E.; Zhou, W.; Peter, S.; Apperley, J.F.; Cortes, J.
32014Bilineal T lymphoblastic and myeloid blast transformation in chronic myeloid leukemia with TP53 mutation-an uncommon presentation in adultsKrishnan, S.; Sabai, K.; Chuah, C. ; Tan, S.Y.
423-Jan-2014Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Jabbour, E.; Kantarjian, H.M.; Saglio, G.; Steegmann, J.L.; Shah, N.P.; Boqué, C.; Chuah, C. ; Pavlovsky, C.; Mayer, J.; Cortes, J.; Baccarani, M.; Kim, D.-W.; Bradley-Garelik, M.B.; Mohamed, H.; Wildgust, M.; Hochhaus, A.
51-Sep-2021Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T CellsLee, Wen-Hsin Sandy; Ye, Zhiyong; Cheung, Alice MS; Goh, YP Sharon; Oh, Hsueh Ling Janice; Rajarethinam, Ravisankar; Yeo, Siok Ping; Soh, Mun Kuen; Li Chan, Esther Hian; Tan, Lip Kun; Tan, Soo-Yong ; Chuah, Charles ; Chng, Wee Joo ; Connolly, John E; Wang, Cheng-I
62015High-throughput genotyping of CRISPR/Cas9-mediated mutants using fluorescent PCR-capillary gel electrophoresisRamlee, M.K; Yan, T ; Cheung, A.M.S ; Chuah, C.T.H ; Li, S 
727-Sep-2012Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutationCortes, J.; Lipton, J.H.; Rea, D.; Digumarti, R.; Chuah, C. ; Nanda, N.; Benichou, A.-C.; Craig, A.R.; Michallet, M.; Nicolini, F.E.; Kantarjian, H.
82014Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibitionNg K.P. ; Manjeri A. ; Lee K.L. ; Huang W. ; Tan S.Y. ; Chuah C.T.H. ; Poellinger L. ; Ong S.T. 
92015Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respirationXiang W.; Cheong J.K. ; Ang S.H. ; Teo B.; Xu P. ; Asari K.; Sun W.T. ; Than H.; Bunte R.M. ; Virshup D.M. ; Chuah C. 
102018The arginase inhibitor N ? -hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional targetNg K.P. ; Manjeri A. ; Lee L.M. ; Chan Z.E. ; Tan C.Y.; Tan Q.D. ; Majeed A. ; Lee K.L. ; Chuah C. ; Suda T. ; Ong S.T. 
112014The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitorsKo T.K. ; Chuah C.T. ; Huang J.W.; Ng K.-P. ; Ong S.T. 
122016The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemiaKo T.K. ; Chin H.S. ; Chuah C.T.H. ; Huang J.W.J.; Ng K.-P. ; Khaw S.L.; Huang D.C.S.; Ong S.T.
132017The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemiaRauzan M. ; Chuah C.T.H. ; Ko T.K. ; Tiong Ong S.